immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of the body’s own immune system to find and kill diseased cells. immunocore has established a robust technology platform which combines monoclonal t cell receptor (mtcr) targeting technology with an effector technology, anti-cd3 scfv, that catalyses the killing of the targeted diseased cells by the host’s own non-specific cytotoxic t cells. immunocore is developing a portfolio of products from the platform, called immtacs, for the treatment of cancer, chronic infectious disease and diabetes.
Company profile
Ticker
IMCR
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Immunocore Ltd
SEC CIK
Corporate docs
Subsidiaries
Immunocore Limited • Immunocore LLC • Immunocore Commercial LLC • Immunocore Ireland Limited • Immunocore GmbH • Immunocore Nominees Limited ...
IMCR stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
8-K
Other Events
5 Apr 24
424B7
Prospectus with selling stockholder info
5 Apr 24
PRE 14A
Preliminary proxy
2 Apr 24
S-8
Registration of securities for employees
20 Mar 24
S-3ASR
Automatic shelf registration
20 Mar 24
8-K
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Immunocore Prices Upsized Convertible Senior Notes Offering
2 Feb 24
Latest ownership filings
4
Leger Tina Amber St
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
SC 13G
FMR LLC
11 Mar 24
SC 13D/A
GENERAL ATLANTIC, L.P.
7 Mar 24
4
David M Berman
1 Mar 24
4
David M Berman
28 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
4
Leger Tina Amber St
21 Feb 24
4
Donato Brian Di
21 Feb 24
4
JOHN GOLL
21 Feb 24
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q3 2023
78.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 125 |
Opened positions | 12 |
Closed positions | 9 |
Increased positions | 50 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 1.90 tn |
Total shares | 39.03 mm |
Total puts | 2.90 k |
Total calls | 212.30 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
RTW Investments | 6.10 mm | $316.40 bn |
Wellington Management | 3.91 mm | $203.11 bn |
Rock Springs Capital Management | 2.94 mm | $152.78 bn |
T. Rowe Price | 2.52 mm | $131.05 bn |
Baker Bros. Advisors | 2.52 mm | $130.83 bn |
FMR | 2.14 mm | $110.87 bn |
Malin Life Sciences | 2.11 mm | $111.40 mm |
Paradigm Biocapital Advisors | 1.38 mm | $71.87 bn |
MS Morgan Stanley | 961.09 k | $49.88 bn |
General Atlantic | 950.00 k | $49.31 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | St Leger Tina Amber | Ordinary Shares | Sell | Dispose S | No | Yes | 64.06 | 4,375 | 280.26 k | 0 |
1 Apr 24 | St Leger Tina Amber | Ordinary Shares | Option exercise | Acquire M | No | Yes | 29.87 | 4,375 | 130.68 k | 4,375 |
1 Apr 24 | St Leger Tina Amber | Employee Share Option Ordinary Shares | Option exercise | Dispose M | No | Yes | 29.87 | 4,375 | 130.68 k | 35,000 |
28 Feb 24 | Berman David M | Ordinary Shares | Sell | Dispose S | No | Yes | 70.45 | 1,200 | 84.54 k | 0 |
28 Feb 24 | Berman David M | Ordinary Shares | Sell | Dispose S | No | Yes | 69.73 | 10,937 | 762.64 k | 1,200 |
28 Feb 24 | Berman David M | Ordinary Shares | Sell | Dispose S | No | Yes | 68.84 | 7,472 | 514.37 k | 12,137 |
28 Feb 24 | Berman David M | Ordinary Shares | Sell | Dispose S | No | Yes | 67.61 | 16,900 | 1.14 mm | 19,609 |
28 Feb 24 | Berman David M | Ordinary Shares | Option exercise | Acquire M | No | Yes | 17.46 | 36,509 | 637.45 k | 36,509 |
28 Feb 24 | Berman David M | Employee Share Option Ordinary Shares | Option exercise | Dispose M | No | Yes | 17.46 | 36,509 | 637.45 k | 271,790 |
27 Feb 24 | Berman David M | Ordinary Shares | Sell | Dispose S | No | Yes | 71.97 | 3,394 | 244.27 k | 0 |
News
Guggenheim Reiterates Buy on Immunocore Hldgs, Maintains $92 Price Target
23 Apr 24
Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
11 Apr 24
Needham Reiterates Buy on Immunocore Hldgs, Maintains $81 Price Target
11 Apr 24
Immunocore Says Selling Shareholders May Offer & Resell Up To 1.2M ADS, Pursuant To Prospectus Supplement
5 Apr 24
JP Morgan Maintains Overweight on Immunocore Hldgs, Raises Price Target to $70
21 Mar 24
Press releases
Immunocore to present at upcoming investor conferences
4 Apr 24
Immunocore presented two posters at CROI 2024
5 Mar 24
Immunocore to present at upcoming investor conferences
1 Mar 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
28 Feb 24
Immunocore Prices Upsized Convertible Senior Notes Offering
30 Jan 24